ski-2053r and Leukopenia

ski-2053r has been researched along with Leukopenia* in 2 studies

Trials

2 trial(s) available for ski-2053r and Leukopenia

ArticleYear
Nephrotoxicity of heptaplatin: a randomized comparison with cisplatin in advanced gastric cancer.
    Cancer chemotherapy and pharmacology, 2002, Volume: 50, Issue:2

    Heptaplatin is a newly developed platinum derivative which has been reported to be less toxic than cisplatin. This study was designed to evaluate the nephrotoxicity of heptaplatin in comparison with that of cisplatin.. Previously untreated advanced gastric cancer patients with normal renal function were randomly assigned into either group I (heptaplatin 400 mg/m(2) i.v. over 1 h on day 1 plus 5-fluorouracil (5-FU) 1000 mg/m(2) per day continuous i.v. from day 1 to day 5), or group II (cisplatin 60 mg/m(2) i.v. over 1 h on day 1 plus 5-FU 1000 mg/m(2) per day continuous i.v. from day 1 to day 5), with the cycles repeated every 4 weeks. Renal function parameters before, during, and after the chemotherapy were compared between the two groups.. A total of 99 patients were enrolled in the study, 51 in group I and 48 in group II. The 24-h proteinuria on day 5 was markedly increased in group I (95+/-108 mg/day to 9098+/-4514 mg/day, means+/-SD) in comparison with the increase observed in group II (104+/-148 mg/day to 151+/-102 mg/day), and creatinine clearance showed a greater decrease in group I (83.1+/-23.6 ml/min to 44.9+/-17.3 ml/min) than in group II (89.6+/-22.1 ml/min to 72.8+/-21.0 ml/min). The differences in these parameters between the two groups were statistically significant throughout the subsequent cycles.. Our findings show that nephrotoxicity was more severe in patients treated with heptaplatin 400 mg/m(2) than with cisplatin 60 mg/m(2) when it was combined with 5-FU. Measures to more effectively prevent nephrotoxicity should be developed for the safe use of heptaplatin.

    Topics: Acute Disease; Adenocarcinoma; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Creatinine; Dexamethasone; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Fluorouracil; Gastrectomy; Humans; Infusions, Intravenous; Kidney Diseases; Kidney Function Tests; Leukopenia; Male; Malonates; Metabolic Clearance Rate; Metoclopramide; Middle Aged; Ondansetron; Organoplatinum Compounds; Proteinuria; Stomach Neoplasms; Survival Analysis; Vomiting

2002
A Phase I study of cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-1,3-dioxolane] platinum(II) in patients with advanced malignancies.
    Cancer, 2001, Apr-15, Volume: 91, Issue:8

    A Phase I study of cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-1,3-dioxolane] platinum(II) (SKI 2053R), a new platinum derivative, was performed to determine the maximum tolerated dose (MTD), the dose limiting toxicities (DLTs), and the pharmacokinetic profile of SKI 2053R in patients with advanced, refractory malignancies.. Twenty-one patients were entered into the study. SKI 2053R was administered with an intravenous infusion over 1 hour every 4 weeks. The SKI 2053R dose was escalated from 40 mg/m(2) up to 480 mg/m(2) using a modified Fibonacci scheme. Pharmacokinetic analysis was done in all patients to determine the total and ultrafiltrable platinum concentrations in both the plasma and the urine.. All patients were evaluable for toxicity and response. There was no significant toxicity with dosages up to 360 mg/m(2). At 480 mg/m(2), two of three patients developed Grade 4 hepatotoxicity, Grade 3 leukopenia and thrombocytopenia, and Grade 2 azotemia and proteinuria. Other toxicity included nausea and emesis, but it was controlled with antiemetics. SKI 2053R did not cause significant neurotoxicity or mucositis. There were 4 patients with stable disease among the 21 patients. Plasma decay of the total and free platinum concentrations was best fitted by using a two-compartment, open model. The terminal plasma half-life of the total platinum after SKI 2053R administration ranged from 63.4 hours to 114.1 hours in dosages ranging from 40 mg/m(2) to 480 mg/m(2) without significant dose dependency. However, the terminal plasma half-life of the free platinum concentration showed a significant dose dependent, incremental pattern. The renal excretion of SKI 2053R measured as platinum ranged from 49% to 75% of the administered dose.. The MTD of SKI 2053R was 480 mg/m(2). The major DLTs were hepatotoxicity, nephrotoxicity, and myelosuppression. The recommended starting dose for a subsequent Phase II study is 360 mg/m(2) once every 4 weeks.

    Topics: Adult; Aged; Antineoplastic Agents; Chemical and Drug Induced Liver Injury; Dose-Response Relationship, Drug; Female; Half-Life; Humans; Infusions, Intravenous; Kidney Diseases; Leukopenia; Male; Malonates; Middle Aged; Neoplasms; Organoplatinum Compounds; Thrombocytopenia

2001